Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts

BACKGROUND: Poly-ADP ribose polymerase (PARP) inhibitor-based cancer therapy selectively targets cells with deficient homologous recombination repair. Considering their long-term use in maintenance treatment, any potential mutagenic effect of PARP inhibitor treatment could accelerate the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Póti, Ádám, Berta, Kinga, Xiao, Yonghong, Pipek, Orsolya, Klus, Gregory T., Ried, Thomas, Csabai, István, Wilcoxen, Keith, Mikule, Keith, Szallasi, Zoltan, Szüts, Dávid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265254/
https://www.ncbi.nlm.nih.gov/pubmed/30425352
http://dx.doi.org/10.1038/s41416-018-0312-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265254/
https://www.ncbi.nlm.nih.gov/pubmed/30425352
http://dx.doi.org/10.1038/s41416-018-0312-6

Ejemplares similares